Detalhe da pesquisa
1.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Blood
; 141(21): 2599-2614, 2023 05 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630605
2.
Development of a Clinical Teaching Unit in Internal Medicine to Promote Interprofessional and Multidisciplinary Learning: A Practical Intervention.
Teach Learn Med
; 33(1): 78-88, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32917107
3.
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Br J Haematol
; 174(3): 397-409, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27098276
4.
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Blood
; 123(5): 706-16, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24319254
5.
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Br J Haematol
; 171(5): 798-812, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26456076
6.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Cancer Cell
; 7(2): 129-41, 2005 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15710326
7.
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood
; 115(21): 4206-16, 2010 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20299508
8.
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.
Blood Cancer J
; 12(4): 50, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365613
9.
Mycetoma caused by Madurella mycetomatis in immunocompromised patients - a case report and systematic literature review.
J Bone Jt Infect
; 7(6): 241-248, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36532293
10.
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
Br J Haematol
; 155(5): 588-98, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21950728
11.
Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
Leukemia
; 35(2): 550-561, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424294
12.
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Blood
; 112(13): 5161-70, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18820131
13.
Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
Oncogene
; 39(13): 2786-2796, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32024967
14.
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
Leukemia
; 34(2): 567-577, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462737
15.
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Sci Rep
; 10(1): 5324, 2020 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32210275
16.
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Mol Cancer Ther
; 7(5): 1121-9, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18445657
17.
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Leukemia
; 33(11): 2685-2694, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30962579
18.
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
Blood Cancer J
; 14(1): 58, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594241
19.
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Mol Cancer Ther
; 6(7): 1951-61, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17620426
20.
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
Clin Cancer Res
; 23(15): 4280-4289, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270494